medigraphic.com

2014, Número 3

<< Anterior Siguiente >>

Rev Med MD 2014; 5.6 (3)


Nuevas terapias antirretrovirales en la infección por VIH

González-Hernández LA, Llamas-Covarrubias MA, González-Vázquez EA, Campos-Loza AE, Arce-Rosas JI, Mercado-Nuñez E, Soria-Rodríguez R, García-Castro JA, Andrade-Villanueva JF

Idioma: Español
Referencias bibliográficas: 21
Paginas: 143-149
Archivo PDF: 1068.46 Kb.


RESUMEN

Existen alrededor de 34 millones de personas que viven con el Virus de la Inmunodeficiencia Humana (VIH) y para ellos la mejor esperanza para evitar una consecuencia fatal por la infección recae en la terapia antirretroviral (ARV), la cual consiste en la combinación de tres drogas que inhiben puntos específicos del ciclo vital del virus. El beneficio de la terapia antirretroviral en reducir la morbimortalidad es clara, sin embargo no es curativa, ya que existen células infectadas de manera latente, llamados reservorios, los cuales evitan la erradicación de la infección.
La terapia antirretroviral, ha cambiado la historia natural de la infección por el virus de inmunodeficiencia humana. En la actualidad, existen más de 20 drogas antirretrovirales las cuales han sido aprobadas por la Food and Drug Administration de Estados Unidos de Norteamérica. Aun así, debido a la aparición de cepas resistentes se encuentran en desarrollo nuevos fármacos que ofrezcan opciones para estos pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.A. Zolopa, R Ortiz, P. Sax, et al. Comparative Study of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each with Elvitegravir, Cobicistat, and Emtricitabine, for HIV Treatment. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. Abstract 99LB.

  2. 2.Rujuta Bam, S Yant, and T Cihlar. Tenofovir Alafenamide (GS-7340) Is Not a Substrate for Renal Organic Anion Transporters (OAT) and Does Not Exhibit OAT-dependent Cytotoxicity. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. Abstract 540.

  3. 3.Saag MS. New and Investigational Antiretroviral Drugs for HIV Infection: Mechanisms of Action and Early Research Findings. Top Antivir Med. 2012 Dec;20(5):162-7. 4.Anderson M, Gilmarti J, Robberechts M, et al. Safety and Antiviral Activity of MK-1439, a Novel NNRTI, in Treatment-naive HIV+ Patients. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 100.

  4. 5.Anderson M, Gilmarti J, Robberechts M, et al. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MK-1439, a Novel HIV NNRTI, in Healthy Subjects. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 527.

  5. 6.Lai M, Feng M, Lu M, et al. Antiviral activity and in vitro mutation development pathways of MK-1439: a novel non-nucleoside reverse transcriptase inhibitor. 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC). September 9-12, 2012. San Francisco. Abstract H-551.

  6. 7.Ferris AL, 2009. Lens epthelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. PNAS 107:3135-3140.

  7. 8.B Desimmie, Frauke Christ, W Thys, J Demeulemeester, D Borrenberghs, R Schrijvers, J Hofkens, N Bannert, and Z Debyser. Viral Particles Produced in Presence of LEDGIN Are Impaired for Infectivity. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. Abstract 104.

  8. 9.Christ F, Voet A, Marchand A, et al. First-in-class Inhibitors of LEDGF/p75-integrase Interaction and HIV replication. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. February 16-19, 2010. Abstract 49.

  9. 10.E Le Rouzic, D Bonnard, S Chasset, J-M Bruneau, F Chevreuil, F Le Strat, S Emiliani, B Ledoussal, F Moreau, and Richard Benarous. Mut101 Integrase- LEDGF Inhibitor Impairs HIV-1 Replication at Two Different Steps, Integration and Production of Infectious Virions after Integration. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 547.

  10. 11.Stephen Yant, L Tsai, C O'Sullivan, T Cihlar, and M Balakrishnan. Non-Catalytic Site Integrase Inhibitors Target the Integrase Domain during Virus Production and Induce a Reverse Transcription Block. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. Abstract 103.

  11. 12.Lalezari, McCallister S, Gigliotti M, et al. A phase 2 safety and efficacy study of bevirimat in heavily treatment experienced HIV+ patients identifies the target phase 3 study profile. 48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). October 25-28, 2008. Washington, DC. Abstract H-891.

  12. 13.E Urano, S Ablan, D Martin, T Nitz, E Freed, and Carl Wild. Potent Antiviral Activity of 2nd Generation Maturation Inhibitors Against Bevirimatresistant Polymorphic HIV-1 Isolates. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 105.

  13. 14.Gathe J, Cade J, DeJesus E, et al. Week-24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with Emtricitabine/Tenofovir, in Treatment-naïve HIV-1+ Adults with CCR5-tropic Virus. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 106LB.

  14. 15.Nowicka-Sans B, et al. Antiviral Activity of a New Small Molecule HIV-1 Attachment Inhibitor, BMS- 626529, the Parent of BMS-663068. 18th Conference on Retroviruses and Opportunistic Infections, abstract 518, Boston, 2011.

  15. 16.Nettles R, et al. Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068: A Potentially First-in-class Oral HIV Attachment Inhibitor. 18th Conference on Retroviruses and Opportunistic Infections, abstract 49, Boston, 2011.

  16. 17.David Langley, R Kimura, P Sivaprakasam, N Zhou, I Dicker, T Wang, J Kadow, N Meanwell, and M Krystal. Homology Models of the Attachment Inhibitor BMS-626529 Bound to gp120 Suggests a Unique Mechanism of Action. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 542.

  17. 18.L Zhu, C Hwang, V Shah, M Hruska, P Hu, B Vakkalagadda, M Furlong, X Xu, G Hanna, and Richard Bertz. Pharmacokinetic Interactions Between BMS-663068, Prodrug of the HIV-1 Attachment Inhibitor BMS-626529, and Ritonavir or Ritonavir-boosted Atazanavir. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 534.

  18. 19.Z. Li, N. Zhou1, Y. Sun, N. Ray, M. Lataillade, G. Hanna, M. Krystal. Activity of the HIV-1 attachment inhibitor BMS-626529 against HIV-1 envelopes resistant to other entry inhibitors. XIX International AIDS Conference, Washington DC, USA. July 22-27, 2012. Abstract TUPE015.

  19. 20.Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral naive adults: 48 week results from SPRING-2 (ING113086). XIX International AIDS Conference. Washington, DC, July 22-27, 2012.

  20. 21.Pozniak A, Mingrone H, Shuldyakov A, et al. Dolutegravir vs raltegravir in ART-experienced, integrase-naive subjects: 24-week interim results from SAILING (ING111762). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 179LB.

  21. 22.Chasity Andrews, A Gettie1, K Russell-Lodrigue, L Moss, H Mohri1, W Spreen, C Cheng-Mayer, Z Hong, M Markowitz, and D Ho. Long-acting Parenteral Formulation of GSK1265744 Protects Macaques against Repeated Intrarectal Challenges with SHIV. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 24LB.




2020     |     www.medigraphic.com